HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $48 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Enanta Pharma (NASDAQ:ENTA) and maintained a price target of $48.
August 08, 2023 | 4:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enanta Pharma's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $48.
The reiteration of the 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Enanta Pharma. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100